Non-alcoholic fatty liver disease (NAFLD) occurs when excess fat ... NAFLD can remain harmless, but in some patients it progresses to non-alcoholic steatohepatitis (NASH). Liver dysfunctions ...

Currently, there are a few available treatment options for liver cancer, including a combination of immunotherapies and a class of drugs known as tyrosine kinase inhibitors (TKIs), but their long-term ...

A Hong Kong researcher has called for more public education about osteoporosis after ... are essential for preventing and managing the disease, increasing bone density and reducing the risk ...

Bansal said. Even with cirrhosis, patients may not feel sick for years, said Dr. Mary Rinella, director of metabolic and fatty liver disease at the University of Chicago Medicine. When liver ...

A Florida doctor who is accused of removing an Alabama man’s liver instead of the spleen, resulting in “immediate and catastrophic death,” had his medical license suspended. In an emergency ...

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a global cause of chronic liver disease. The prevalence of ...

The Union Health Ministry has introduced revised operational guidelines and a training module for Non-Alcoholic Fatty Liver Disease (NAFLD) to enhance patient care. NAFLD is a growing public ...

The Union Health Ministry released the revised Operational Guidelines and Training Module of Non-Alcoholic Fatty Liver Disease, here today. These documents are designed ... It also reinforces the ...

As liver disease progresses, symptoms will vary. Patients may experience fatigue, jaundice or ascites, which is an accumulation of fluid in the abdomen, Carr says. “Most commonly, people are not ...

Attention has now shifted to using LXR inhibitors to reduce triglyceride buildup and treat metabolic dysfunction-associated steatotic liver disease (MASLD). While LXR-inverse agonists show promise ...

Our findings are clinically important because we identified CYP1B1 as a predictor of HSC and liver fibrosis in patients, which may help with the early diagnosis of this disease. More importantly ...